Healthcare earnings beat: 96% of S&P 500 firms top EPS estimates
According to Seeking Alpha, 22 of 23 S&P 500 healthcare companies reporting in the third quarter beat EPS expectations.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Seeking Alpha, healthcare earnings for the S&P 500 in the third quarter were broadly strong. Of the 23 companies that reported last week, 22 (96%) beat EPS expectations, while one fell short. On revenue, 21 companies (91%) exceeded consensus, and all 23 posted year-over-year growth.
Eli Lilly drew the most attention, with revenue up 39% on demand for Mounjaro and Zepbound, and Regeneron posted 36% revenue growth. Several firms raised their 2026 outlooks, though Bristol Myers Squibb lowered its adjusted EPS forecast.
why it matters
Strong results from large drugmakers support the healthcare sector and the broader S&P 500. Still, Bristol Myers Squibb's cut to its EPS outlook shows that revenue growth does not always translate into higher profit.
market impact
Healthcare sector: strong reports support drugmaker shares
- S&P 500 healthcare sector pressure up — most companies beat revenue and earnings expectations
tags
instruments
sources
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growth — Seeking Alpha, 31 October 2026 at 14:40 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗